|
|
戈谢病治疗的研究进展
|
Abstract:
戈谢病是一种罕见病，可累及肝脏、脾脏、骨骼等多种组织器官，引发多种并发症，常见的临床表现有肝脏肿大，脾脏肿大，贫血，血小板减少，骨坏死等，酶替代治疗等治疗方法可以缓解症状，但骨坏死等并发症一旦出现不可逆转。确诊戈谢病之后及早进行治疗是治疗戈谢病的关键。及时治疗可以控制病情进展，防止不可逆并发症出现，减轻患者痛苦，提高患者的生活质量。
Gaucher disease is a rare disease that can affect the liver, spleen, bone and other organs, leading to a variety of complications. Common clinical manifestations include hepatomegaly, Splenomegaly, anemia, thrombocytopenia and osteonecrosis. Enzyme replacement therapy and other treatments can alleviate symptoms, but complications such as osteonecrosis cannot be reversed once they occur. Early diagnosis and treatment are crucial for the management of Gaucher disease. Timely treatment can control disease progression, prevent irreversible complications, reduce patient suffering and improve the quality of life.
| [1] | Nalysnyk, L., Rotella, P., Simeone, J.C., Hamed, A. and Weinreb, N. (2016) Gaucher Disease Epidemiology and Natural History: A Comprehensive Review of the Literature. Hematology, 22, 65-73. https://doi.org/10.1080/10245332.2016.1240391 |
| [2] | Zion, Y.C., Pappadopulos, E., Wajnrajch, M., et al. (2016) Re-Thinking Fatigue in Gaucher Disease. Orphanet Journal of Rare Diseases, 29, 1-7. |
| [3] | Rosenbloom, B.E. and Weinreb, N.J. (2013) Gaucher Disease: A Comprehensive Review. Critical Reviews in Oncogenesis, 18, 163-175. https://doi.org/10.1615/critrevoncog.2013006060 |
| [4] | Lo, S.M., Stein, P., Mullaly, S., Bar, M., Jain, D., Pastores, G.M., et al. (2010) Expanding Spectrum of the Association between Type 1 Gaucher Disease and Cancers: A Series of Patients with up to 3 Sequential Cancers of Multiple Types—Correlation with Genotype and Phenotype. American Journal of Hematology, 85, 340-345. https://doi.org/10.1002/ajh.21684 |
| [5] | Thomas, A.S., Mehta, A.B. and Hughes, D.A. (2013) Diagnosing Gaucher Disease: An On-Going Need for Increased Awareness amongst Haematologists. Blood Cells, Molecules, and Diseases, 50, 212-217. https://doi.org/10.1016/j.bcmd.2012.11.004 |
| [6] | 中国成人戈谢病诊治专家共识(2020) [J]. 中华医学杂志, 2020, 100(24): 1841-1849. |
| [7] | Revel‐Vilk, S., Szer, J., Mehta, A. and Zimran, A. (2018) How We Manage Gaucher Disease in the Era of Choices. British Journal of Haematology, 182, 467-480. https://doi.org/10.1111/bjh.15402 |
| [8] | 中华医学会儿科学分会遗传代谢内分泌学组, 中华医学会儿科学分会血液学组, 中华医学会血液学分会红细胞疾病(贫血)学组. 中国戈谢病诊治专家共识(2015) [J]. 中华儿科杂志, 2015, 53(4): 256‐261. |
| [9] | El-Beshlawy, A., Tylki-Szymanska, A., Vellodi, A., Belmatoug, N., Grabowski, G.A., Kolodny, E.H., et al. (2017) Long-term Hematological, Visceral, and Growth Outcomes in Children with Gaucher Disease Type 3 Treated with Imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 120, 47-56. https://doi.org/10.1016/j.ymgme.2016.12.001 |
| [10] | Hobbs, J.R., Shaw, P.J., Jones, K.H., Lindsay, I. and Hancock, M. (1987) Beneficial Effect of Pre-Transplant Splenectomy on Displacement Bone Marrow Transplantation for Gaucher’s Syndrome. The Lancet, 329, 1111-1115. https://doi.org/10.1016/s0140-6736(87)91673-4 |
| [11] | 韩冰, 陈苗, 杨辰. 戈谢病多学科诊疗专家共识(2020) [J]. 协和医学杂志, 2020, 11(6): 682-697. |
| [12] | Orenstein, M., Barbouth, D., Bodamer, O.A. and Weinreb, N.J. (2014) Patients with Type 1 Gaucher Disease in South Florida, USA: Demographics, Genotypes, Disease Severity and Treatment Outcomes. Orphanet Journal of Rare Diseases, 9, Article No. 45. https://doi.org/10.1186/1750-1172-9-45 |
| [13] | Essabar, L., Meskini, T., Lamalmi, N., Ettair, S., Erreimi, N. and Mouane, N. (2015) Gaucher’s Disease: Report of 11 Cases with Review of Literature. Pan African Medical Journal, 20, Article No. 18. https://doi.org/10.11604/pamj.2015.20.18.4112 |
| [14] | 张博健, 乔海泉. 戈谢病的外科研究进展[J]. 腹部外科, 2019, 32(2): 144-147. |
| [15] | Motta, I., Filocamo, M., Poggiali, E., Stroppiano, M., Dragani, A., Consonni, D., et al. (2015) A Multicentre Observational Study for Early Diagnosis of Gaucher Disease in Patients with Splenomegaly and/or Thrombocytopenia. European Journal of Haematology, 96, 352-359. https://doi.org/10.1111/ejh.12596 |
| [16] | Zimmermann, A., Popp, R.A., Al-Khzouz, C., Bucerzan, S., Naşcu, I., Leucuta, D., et al. (2016) Cholelithiasis in Patients with Gaucher Disease Type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. Journal of Gastrointestinal and Liver Diseases, 25, 447-455. https://doi.org/10.15403/jgld.2014.1121.254.zim |
| [17] | Zimran, A., Brill-Almon, E., Chertkoff, R., Petakov, M., Blanco-Favela, F., Muñoz, E.T., et al. (2011) Pivotal Trial with Plant Cell-Expressed Recombinant Glucocerebrosidase, Taliglucerase Alfa, a Novel Enzyme Replacement Therapy for Gaucher Disease. Blood, 118, 5767-5773. https://doi.org/10.1182/blood-2011-07-366955 |
| [18] | Weinreb, N., Taylor, J., Cox, T., Yee, J. and vom Dahl, S. (2008) A Benchmark Analysis of the Achievement of Therapeutic Goals for Type 1 Gaucher Disease Patients Treated with Imiglucerase. American Journal of Hematology, 83, 890-895. https://doi.org/10.1002/ajh.21280 |
| [19] | Gary, S.E., Ryan, E., Steward, A.M. and Sidransky, E. (2018) Recent Advances in the Diagnosis and Management of Gaucher Disease. Expert Review of Endocrinology & Metabolism, 13, 107-118. https://doi.org/10.1080/17446651.2018.1445524 |
| [20] | Giraldo, P., Andrade-Campos, M., Alfonso, P., Irun, P., Atutxa, K., Acedo, A., et al. (2018) Twelve Years of Experience with Miglustat in the Treatment of Type 1 Gaucher Disease: The Spanish ZAGAL Project. Blood Cells, Molecules, and Diseases, 68, 173-179. https://doi.org/10.1016/j.bcmd.2016.10.017 |
| [21] | Hollak, C.E.M., Hughes, D., van Schaik, I.N., Schwierin, B. and Bembi, B. (2009) Miglustat (Zavesca®) in Type 1 Gaucher Disease: 5‐Year Results of a Post‐Authorisation Safety Surveillance Programme. Pharmacoepidemiology and Drug Safety, 18, 770-777. https://doi.org/10.1002/pds.1779 |
